Becker's Healthcare May 16, 2024
Paige Twenter

The FDA has granted accelerated approval to Bristol Myers Squibb’s Breyanzi, a CAR T-cell therapy indicated for types of lymphoma and leukemia.

Breyanzi (lisocabtagene maraleucel) is now approved for adults with relapsed or refractory follicular lymphoma who have received at least two other systemic therapies, according to a May 15 news...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
President-elect Trump's picks for CDC, FDA, surgeon general: 31 notes
Opinion: RFK Jr. and MAHA should champion a Marshall Plan for obesity
Trump picks Johns Hopkins surgeon to head FDA: 10 things to know
Will Trump's healthcare appointments bring 'radical changes'?
The Trump picks who want to reform health care

Share This Article